SG Americas Securities
PRVB

SG Americas Securities’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

SG Americas Securities’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-49,156
Closed -$1.19M – 3455
2023
Q1 		$1.19M Buy
49,156
+38,802
+375% +$487K 0.01% 1030
2022
Q4 		$109K Buy
+10,354
New +$83.6K ﹤0.01% 2660
2022
Q1 		– Sell
-13,990
Closed -$79K – 3604
2021
Q4 		$79K Sell
13,990
-148,829
-91% -$945K ﹤0.01% 3127
2021
Q3 		$1.04M Buy
162,819
+34,372
+27% +$221K ﹤0.01% 1873
2021
Q2 		$1.08M Buy
128,447
+10,221
+9% +$82.5K 0.01% 1518
2021
Q1 		$1.24M Buy
118,226
+96,778
+451% +$1.36M 0.01% 1379
2020
Q4 		$363K Sell
21,448
-134,869
-86% -$2.02M ﹤0.01% 2229
2020
Q3 		$2.01M Buy
156,317
+98,405
+170% +$1.24M 0.01% 739
2020
Q2 		$817K Buy
+57,912
New +$731K 0.01% 1614
2019
Q4 		– Sell
-40,683
Closed -$278K – 3493
2019
Q3 		$278K Buy
+40,683
New +$411K ﹤0.01% 2193

Other funds holding PRVB

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

SG Americas Securities's PRVB Position: Q2 2023 in Review

SG Americas Securities sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 49,156 shares — an estimated $1.19M sold.

SG Americas Securities first reported a position in PRVB in Q3 2019 and held it in 10 quarters. The position peaked at $2.01M in Q3 2020. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • SG Americas Securities reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • SG Americas Securities sold 49,156 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $1.19M.
  • SG Americas Securities first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 10 quarters.
  • SG Americas Securities's Provention Bio, Inc. Common Stock position peaked at $2.01M in Q3 2020.
  • 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on SG Americas Securities's 13F filing for Q2 2023, filed 10 Jul 2023.